Taken together, we have identified a significant relationship between STAT3 and ANGPTL4 in GBM stem cells and their therapeutic value as biomarkers in targeting the GSC subpopulation of Mesenchymal GBM. This evidence concerns the gene ANGPTL4 and glioblastoma.